<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639609</url>
  </required_header>
  <id_info>
    <org_study_id>2020-007</org_study_id>
    <secondary_id>2020-A01272-37</secondary_id>
    <nct_id>NCT04639609</nct_id>
  </id_info>
  <brief_title>Characterization of Neuromuscular Function and Fatigue After Breast Cancer Treated With Adjuvant Chemotherapy (PROTECT-04)</brief_title>
  <acronym>PROTECT-04</acronym>
  <official_title>Characterization of Neuromuscular Function and Fatigue After Breast Cancer Treated With Adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de cancérologie Strasbourg Europe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UR 3072 - Mitochondrie, Stress oxydant et Protection musculaire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de cancérologie Strasbourg Europe</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a transversal monocentric study comparing two groups of women (group 1, patient group&#xD;
      : patients who have been treated for a breast cancer with taxane-based chemotherapy ; group&#xD;
      2, control group : healthy volunteers). The aim of this study is to evaluate if a difference&#xD;
      exists regarding the maximal isometric muscle strength between group 1 and 2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will be evaluated a single time during two hours. For patients from group 1 the&#xD;
      evaluation should take place within the two weeks that follow the end of adjuvant treatment.&#xD;
      There is no specificity regarding evaluation of volunteers from group 2, their evaluation can&#xD;
      take place at any time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 29, 2020</start_date>
  <completion_date type="Actual">September 6, 2021</completion_date>
  <primary_completion_date type="Actual">September 6, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal isometric muscle strength for knee extensors</measure>
    <time_frame>At Inclusion</time_frame>
    <description>Measured with force sensors. Significant differences between the two groups will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with neuromuscular fatigue</measure>
    <time_frame>At Inclusion</time_frame>
    <description>Assessment using surface electromyography. Significant differences between the two groups will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with neuromuscular fatigue</measure>
    <time_frame>At Inclusion</time_frame>
    <description>Assessment using percutaneous electric nerve stimulation. Significant differences between the two groups will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with neuromuscular fatigue</measure>
    <time_frame>At Inclusion</time_frame>
    <description>Assessment using transcranial magnetic stimulation. Significant differences between the two groups will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with subjective fatigue.</measure>
    <time_frame>At Inclusion</time_frame>
    <description>Questionnaire Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) version 4.&#xD;
Significant differences between the two groups will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with muscle architecture.</measure>
    <time_frame>At Inclusion</time_frame>
    <description>Assessment using muscle ultrasonography. Significant differences between the two groups will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with body composition.</measure>
    <time_frame>At Inclusion</time_frame>
    <description>Assessment using bio-impedance analysis. Significant differences between the two groups will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1 : Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 : healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Characterization of Neuromuscular Function and Fatigue</intervention_name>
    <description>at inclusion</description>
    <arm_group_label>Group 1 : Patients</arm_group_label>
    <arm_group_label>Group 2 : healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
        Group 1 - Patients :&#xD;
&#xD;
          -  Give written inform consent&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Affiliate to social security system&#xD;
&#xD;
          -  Ability to speak, understand and read French&#xD;
&#xD;
          -  Breast cancer, Stage II or III, treated by taxane-based chemotherapy&#xD;
&#xD;
        Group 2 - Control group :&#xD;
&#xD;
          -  Give written inform consent&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Affiliate to social security system&#xD;
&#xD;
          -  Ability to speak, understand and read French&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Group 1 - Patients :&#xD;
&#xD;
          -  &lt; 18 years old or patients ≥ 18 years old under guardianship, or supervision&#xD;
&#xD;
          -  Psychiatric, musculoskeletal or neurologic disorders&#xD;
&#xD;
          -  Patients presenting one of the following contraindications to transcranial magnetic&#xD;
             stimulation :&#xD;
&#xD;
          -  Presence of a implanted metallic foreign-body (cochlear implant, drug pump system,&#xD;
             pacemaker, etc.)&#xD;
&#xD;
          -  History of epilepsy&#xD;
&#xD;
          -  Brain injury (vascular, traumatic, tumour-induced, infectious or metabolic)&#xD;
&#xD;
          -  Women that are pregnant&#xD;
&#xD;
          -  Serious or recent heart disease&#xD;
&#xD;
        Group 2 -Control group :&#xD;
&#xD;
          -  &lt; 18 years old or patients ≥ 18 years old under guardianship, or supervision&#xD;
&#xD;
          -  Psychiatric, musculoskeletal or neurologic disorders&#xD;
&#xD;
          -  Pacemaker implantation&#xD;
&#xD;
          -  History of cancer&#xD;
&#xD;
          -  All known chronic disease&#xD;
&#xD;
          -  Subjects presenting one of the following contraindications to transcranial magnetic&#xD;
             stimulation :&#xD;
&#xD;
          -  Presence of a implanted metallic foreign-body (cochlear implant, drug pump system,&#xD;
             pacemaker, etc.)&#xD;
&#xD;
          -  History of epilepsy&#xD;
&#xD;
          -  Brain injury (vascular, traumatic, tumour-induced, infectious or metabolic)&#xD;
&#xD;
          -  Women that are pregnant&#xD;
&#xD;
          -  Serious or recent heart disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut de Cancerologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

